Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1451 to 1500 of 4090 results for patient

  1. Renal cell carcinoma Pathways Pilot [ID6186]

    In development Reference number: GID-TA11186 Expected publication date: TBC

  2. Transilluminated powered phlebectomy for varicose veins (HTG16)

    Evidence-based recommendations on transilluminated powered phlebectomy for varicose veins. This involves using a special light passed underneath the skin to see the veins and removing them by suction.

  3. NICE decision aid: process guide (PMG42)

    This process guide provides an overview of the key principles used for developing NICE decision aids. It ensures that robust, quality-assured decision aids for people using and providing health and social care services are developed in an open, transparent and timely way, with appropriate input from key groups

  4. Percutaneous mitral valve leaflet repair for mitral regurgitation (HTG513)

    Evidence-based recommendations on percutaneous mitral valve leaflet repair for mitral regurgitation in adults. This involves attaching a clip to the leaflets of the mitral valve.

  5. Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease (HTG318)

    Evidence-based recommendations on endoscopic radiofrequency ablation for gastro-oesophageal reflux disease. This involves using heat from electrodes to change the tissues in the oesophagus, with the aim of reducing symptoms.

  6. Axonics sacral neuromodulation system for treating refractory overactive bladder (HTG554)

    Evidence-based recommendations on Axonics sacral neuromodulation system for treating refractory overactive bladder.

  7. Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)

    Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

  8. Phrenic nerve transfer in brachial plexus injury (HTG322)

    Evidence-based recommendations on phrenic nerve transfer in brachial plexus injury. This involves finding the phrenic nerve, cutting it and joining it to the damaged nerve in the brachial plexus.

  9. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]

    In development Reference number: GID-HST10063 Expected publication date: TBC

  10. Living-donor lung transplantation for end-stage lung disease (HTG111)

    Evidence-based recommendations on living-donor lung transplantation for end-stage lung disease. This involves removing a lung from each of the two donors and replacing the recipient's lungs with the donor lungs.

  11. Somatrogon for treating growth disturbance in children and young people aged 3 years and over (TA863)

    Evidence-based recommendations on somatrogon (Ngenla) for treating growth disturbance in children and young people aged 3 years and over.

  12. Our role in the Innovative Licensing and Access Pathway (ILAP)

    The Innovative Licensing and Access Pathway (ILAP) is a unique initiative which works with medicine developers early on to help get new medicines to patients faster.

  13. Depression in adults: treatment and management (NG222)

    This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.

  14. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin (TA159)

    Evidence-based recommendations on spinal cord stimulation for chronic pain of neuropathic or ischaemic origin in adults.

  15. Asthma: objective tests (IND272)

    This indicator covers the percentage of patients with a new diagnosis of asthma on or after (start date) with a record of an objective test between 3 months before or 3 months after diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  16. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer (TA1122)

    Evidence-based recommendations on amivantamab (Rybrevant) with lazertinib (Lazcluze) for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.

  17. Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (TA827)

    Evidence-based recommendations on azacitidine (Onureg) for maintenance treatment of acute myeloid leukaemia after induction therapy in adults.

  18. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer (TA1060)

    Evidence-based recommendations on osimertinib (Tagrisso) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.

  19. Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)

    Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.

  20. Myocardial infarction: PCI rates (IND74)

    This indicator covers the time between call for help and balloon inflation for patients with ST segment elevation myocardial infarction (STEMI) undergoing reperfusion by primary percutaneous coronary intervention (PCI). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG93

  21. Myocardial infarction: PCI in less than 60 minutes (IND73)

    This indicator covers the proportion of patients with ST-segment elevation myocardial infarction (STEMI) who had balloon inflation for primary percutaneous coronary intervention (PCI) in less than 60 minutes from time of admission at a centre with primary PCI facilities. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG92

  22. Chronic kidney disease: assessment and management (NG203)

    This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.

  23. Pembrolizumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]

    In development Reference number: GID-TA11694 Expected publication date:  10 February 2027

  24. Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest (MIB112)

    NICE has developed a medtech innovation briefing (MIB) on Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest .

  25. Spectra Optia for automatic red blood cell exchange in people with sickle cell disease (HTG405)

    Evidence-based recommendations on Spectra Optia for automated red blood cell exchange in people with sickle cell disease.

  26. SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea (MIB190)

    NICE has developed a medtech innovation briefing (MIB) on SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea .

  27. Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)

    Evidence-based recommendations on mavacamten (Camzyos) for symptomatic obstructive hypertrophic cardiomyopathy.

  28. National implementation team

    prescribing Measuring the use of NICE guidance Into practice resources Patient decision aids NICE and health inequalities Implementation...

  29. Knowledge transfer seminars

    Learn from NICE International, part of the UK's National Institute for Health and Care Excellence, about how to improve your nation's health and wellbeing

  30. Implantation of a left ventricular assist device for destination therapy in people ineligible for heart transplantation (HTG369)

    Evidence-based recommendations on implantation of a left ventricular assist device for destination therapy in people ineligible for heart transplantation.

  31. Single-step scaffold insertion for repairing symptomatic chondral knee defects (HTG728)

    Evidence-based recommendations on single-step scaffold insertion for repairing symptomatic chondral knee defects. This involves inserting a scaffold into the damaged area of the knee to support regrowth and repair of the cartilage.

  32. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia (HTG639)

    Evidence-based recommendations on prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves positioning a temporary implant in the urethra to increase the flow of urine.

  33. Balloon kyphoplasty for vertebral compression fractures (HTG108)

    Evidence-based recommendations on balloon kyphoplasty for vertebral compression fractures. This involves inflating baloon-like devices placed into the collapsed vertebra until it reaches normal height, after which they are removed and replaced with a special cement.

  34. Image-guided radiofrequency excision biopsy of breast lesions (HTG198)

    Evidence-based recommendations on image-guided radiofrequency excision biopsy of breast lesions. This involves inserting a probe that uses radiofrequency energy to cut through the breast internally, and removing the lump with a small area of surrounding tissue to test for cancer.

  35. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)

    Evidence-based recommendations on trastuzumab (Herceptin) for treating HER2-positive metastatic gastric cancer in adults.

  36. Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)

    Evidence-based recommendations on nivolumab–relatlimab (Opdualag) for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over.

  37. Abaloparatide for treating osteoporosis after menopause (TA991)

    Evidence-based recommendations on abaloparatide (Eladynos) for treating osteoporosis after menopause in women, trans men and non-binary people with a very high risk of fracture.

  38. Oral health: local authorities and partners (PH55)

    This guideline covers improving oral health by developing and implementing a strategy that meets the needs of people in the local community. It aims to promote and protect people’s oral health by improving their diet and oral hygiene, and by encouraging them to visit the dentist regularly.

  39. Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413]

    In development Reference number: GID-TA11488 Expected publication date:  15 July 2026

  40. Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]

    In development Reference number: GID-TA11638 Expected publication date: TBC

  41. Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)

    Evidence-based recommendations on bortezomib (Velcade) for treating multiple myeloma before chemotherapy and stem cell transplant in adults.

  42. Percutaneous insertion of craniocaudal expandable implants for vertebral compression fracture (HTG422)

    Evidence-based recommendations on percutaneous insertion of craniocaudal expandable implants for vertebral compression fracture in adults. This involves inserting an implant into the spine to restore the vertebral height.

  43. Deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults (HTG577)

    Evidence-based recommendations on deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults. This involves implanting an electrode in the brain and an electrical stimulator under the skin on the chest.

  44. Ambulight PDT for the treatment of non-melanoma skin cancer (HTG268)

    Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.

  45. Thermogard XP for therapeutic hypothermia after cardiac arrest (MIB37)

    NICE has developed a medtech innovation briefing (MIB) on Thermogard XP for therapeutic hypothermia after cardiac arrest

  46. Healthy.io test for home testing of urine albumin to creatinine ratio (MIB221)

    NICE has developed a medtech innovation briefing (MIB) on Healthy.io test for home testing of urine albumin to creatinine ratio .

  47. Combined endoscopic and laparoscopic removal of colonic polyps (HTG354)

    Evidence-based recommendations on combined endoscopic and laparoscopic removal of colonic polyps. This involves using an endoscope in the bowel plus keyhole surgery through the skin of the abdomen to remove colonic polyps.

  48. Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.

  49. SimpliCT laser-guided needle placement in interventional radiology (MIB98)

    NICE has developed a medtech innovation briefing (MIB) on SimpliCT laser-guided needle placement in interventional radiology .